4.8 Article

Molecular imaging of activated platelets via antibody-targeted ultrasmall iron oxide nanoparticles displaying unique dual MRI contrast

Journal

BIOMATERIALS
Volume 134, Issue -, Pages 31-42

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2017.04.037

Keywords

Molecular imaging; Dual contrast iron oxide nanoparticle; Magnetic resonance imaging; Sortase; Platelet; Cardiovascular disease

Funding

  1. National Health and Medical Research Council [APP1037310]
  2. University of Queensland Early Career Grant [UQECR1606713]
  3. Australian Research Council [CE140100036, FT0992210]
  4. National Heart Foundation [CR 11M6066, 100517]
  5. National Natural Science Foundation of China [81471657, 81527901]
  6. Australian Research Council [FT0992210] Funding Source: Australian Research Council

Ask authors/readers for more resources

Magnetic resonance imaging (MRI) is a powerful and indispensable tool in medical research, clinical diagnosis, and patient care due to its high spatial resolution and non-limited penetration depth. The simultaneous use of positive and negative MRI imaging that employs the same contrast agents will significantly improve detection accuracy. Here we report the development of functional multimodal iron oxide nanoparticles for targeted MRI of atherothrombosis using a combination of chemical and biological conjugation techniques. Monodisperse, water-soluble and biocompatible ultra-small magnetic dual contrast iron oxide nanoparticles (DCIONs) were generated using a high-temperature co-precipitation route and appeared to be efficient positive and negative dual contrast agents for magnetic resonance imaging. Using a unique chemo-enzymatic approach involving copper-free click chemistry and Staphylococcus aureus sortase A enzyme conjugation, DCIONs were functionalized with single-chain antibodies (scFv) directed against activated platelets for targeting purposes. The DCIONs were also labelled with fluorescent molecules to allow for optical imaging. The antigen binding activity of the scFv was retained and resulted in the successful targeting of contrast agents to thrombosis as demonstrated in a range of in vitro and in vivo experiments. T-1- and T-2-weighted MRI of thrombi was recorded and demonstrated the great potential of dual T-1/T-2 contrast iron oxide particles in imaging of cardiovascular disease. (C) 2017 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available